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The purpose of this thesis was to determine whether K-opioid 
and a2-noradrenergic systems interact when mediating the 
ultrasphic vocalizatidns ,(yS¥) and Idcomotor activity of
 
preweanling rats. In order to determine whether these
 
neurotransmitter systems interact, rats were treated with
 
various combinations of K-opioid and a?.-noradrenergic
 
agonist and antagonist drugs. It was predicted that k-

opioid ahd af-ndradrenergic systems would interact to
 
mediate USV production, but not the locomotor activity, of
 
11-day-old rats. In the first experiment, USVs and line-

crosses were measured for 20 min after rat pups were given
 
an injection of saline or the a2-noradrenergic agonist
 
clonidine (0.05, 0.1, 0.25, or 0.5 mg/kg, ip). Clonidine
 
caused a dose-dependent increase in USV production and
 
reduced locomotor activity. In the second experiment,
 
interaction of the K-opioid and the a2-noradrenergic systems
 
was examined by injecting rats with the K-opioid antagonist
 
nor-BNI (0, 5, or 10 mg/kg, ip), followed by an injection
 
of saline, the K-opioid agonist U50,488 (2.5 mg/kg, ip), or
 
clonidine (0.25 mg/kg, ip). nor-BNI reduced USD,488-, but
 
111
 
not clonidine-> induced USV production. nor-BNI also
 
decreased U50,488-induced line-crosSes. In the third
 
experiment., : the interaction of K-opioid and a2-noradrenergiC:
 
systems was further examined by co-administering the a2­
noradrenergic antagonist yohimbine (0.0, 0.5, or 1.0 mg/kg,
 
ip) and salirie, U50,488 (2.5 mg/kg), or clonidine (0.25
 
mg/kg). interestingly, yohimbine decreased both U50,488-'
 
and clonidine-induced USV production. Yohimbine also
 
reduced U50,488-.ind,uced line-crosses. These findings
 
confirm that k-opioid and a2-noradrenergic systems interact
 
to mediate USV production, however the pattern of the
 
interaction was more complex than originally predicted. .
 
More specifically, K-opioid and a2-noradrenergic systems
 
interact in a unidirectional manner when mediating USV
 
production, with the K-opioid receptors located "up-stream"
 
from the noradrenergic neurons.
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Introduction
 
Animal models of distress and anxiety
 
Distress and anxiety have been extensively
 
investigated using a variety of animal models. For
 
instance, behavioral studies have shown that adult rats
 
often urinate, defecate, and exhibit increased exploratory
 
behaviors, all of which are measures of anxiety in rats
 
(Archer, 1973; Crawley, 1985; Russell, 1973; Walsh &
 
Cummins, 1976). In addition, anxiety reduces the locomotor
 
activity of rats in the open arms of an elevated plus-maze
 
(Fellow, Chopin, File, & Briley, 1985). There are many
 
physiological correlates with anxiety and distress, as
 
anxious rats and mice have enhanced levels of plasma
 
corticosterone and other stress-related hormones (Hennessy
 
& Levine, 1979; Misslin & Cigrang, 1986). Therefore, it
 
appears that anxiety and distress can,be assessed in adult
 
rats using both behavioral and physiological measures.
 
In contrast to adult models, developmental animal
 
models of distress and anxiety are limited due to size of
 
the young rat, physiological immaturity, and inability to
 
perform required tasks. Therefore, more Suitable behaviors
 
must be used to accurately assess distress anxiety in young
 
rats. One commonly used measure of distress anxiety is
 
ultrasonic vocalizations (USV). USVs are often considered
 
to be an emotionally-mediated behavipr that may reflect
 
distress in young rodents (Winslow & Insel, 1991a). Nearly
 
45 years ago, Zippelius and Schleidt (as cited in Hofer &
 
Shair, 1978) found that young mice emit USVs when isolated
 
from the dam. Since then various investigators have
 
examined the behavioral and neurochemical characteristics
 
of ultrasound production in rats and mice.
 
Characteristics of USVs in young and adult rats.
 
Since their discovery 45 years ago, USVs have been
 
rigorously studied in neonatal and preweanling rats. USVs
 
produced by young rats range from 30-50 kHz, which is
 
beyond the range of human hearing (Noirot, 1968; Sewell,
 
1970) Young rats begin emitting USVs shortly after birth,
 
with the frequency of vocalizations increasing until they
 
reach a peak at 10 to 13 days of age. USVs decline soon
 
after this time, and are almost completely absent after 20
 
days of age (Hofer & Shair, 1978; Kehoe & Harris, 1989,*
 
Noirot, 1968). Adult rats also emit USVs, but these calls
 
typically range between 20-24 kHz (Thomas, Takahashi, &
 
Barfield, 1983). These vocalizations are produced as rats
 
engage in copulation and aggressive behaviors (Cagiano et
 
al., 1989; Thomas et al., 1983). Altogether, it appears
 
 that ultrasound production undergoes a number of
 
ontogenetic changes: First, the total number of USVs
 
produced by rats declines across ontogeny and, second,
 
situations resulting in the production of USVs show age-

dependent differences.
 
; Distress and cardiovascular models of USVs. In recent
 
years, controversy has developed about the role of USVs in
 
young rodents. Specifically, USVs were originally
 
interpreted to be an emotionally-mediated behavior
 
exhibited by young rats (Noirot, 1968); however/ Blumberg
 
and colleagues have challenged this view by providing
 
evidence that USVs are by-products of changes that occur in
 
the cardiovascular system (Blumberg, Sokoloff, & Kent,
 
1999).
 
The distress model. In neonatal and preweanling rats,
 
USVs are emitted when the pup is separated from its
 
littermates and dam (Hofer & Shair, 1978; Noirot, 1972).
 
This separation causes the pup to produce ultrasounds that
 
elicit maternal retrieval, caregiving, and aid in
 
thermoregulation (Bell, 1979; Hofer & Shair, 1978; Sales &
 
Smith, 1978; Smotherman et al., 1974). Thus, separation
 
from the dam and littermates is presumed to be distressing
 
to the young pup and the resulting vocalizations are
 
interpreted to be a product of their emotional state.
 
Frequency of isolation-induced USVs can be altered by
 
various factors, such as cold temperature, presentation of
 
the dam, and presentation of an unfamiliar adult male. For
 
. 	instance, rat pups emit USVs when isolated,in a cold
 
environment (Allin & Banks, 1971; Blumberg et al., 1998).
 
USVs emitted during cold exposure provoke maternal
 
retrieval for assistance in thermoregulation (Allin &
 
Banks, 1971). Hence, USVs may be emitted to resolve
 
physiological discomfort experienced in a cold environment.
 
Besides being temperature dependent, USVs can be
 
altered in various social situations. For example, an
 
isolated pup will decrease its vocalizations when an
 
anesthetized dam is presented to the pup (Garden & Hofer,
 
1992). The decrease in vocalizations is independent of the
 
dam's ability to assist in the thermoregulation of the pup,
 
because pups will decrease their vocalizations even when
 
the dam's body temperature is significantly below normal
 
levels (Garden & Hofer, 1992; Hofer, Brunelli, & Shair,
 
1993), Upon removal of the dam, the rat pup emits
 
vocalizations at an even, greater rate than it did initially
 
(known as potentiation; Hofer, Masmela, Brunelli, & Shair,
 
1998). However, suppression of USVs and motor; movement
 
(i.e., freezing) is observed when an unfamiliar adult male
 
is placed in the same environment with the rat pup
 
(Takahashi, 1992). Interestingly, the isolated rat pup
 
continues to remain quiet after the unfamiliar male is
 
removed (known as inhibition; Shair, Masmeia, & Hofer,
 
1999). The potentiation and inhibition of USVs appears to
 
be emotionally-mediated, because young rats exposed to
 
extreme cold temperatures also increase their USVs or
 
remain quiet upon removal of the dam (or an adult male
 
(Shair,, Masmeia, Brunelli, &/Hofer, 1997). In summary, it
 
is evident that isolation-induced USV production can be
 
modulated by various situational factors.
 
Psychopharmacological manipulations are capable of
 
modulating separation-induced USVs. Drugs that are known
 
to be rewarding (e.g., morphine and cocaine) or anxiety
 
reducing (e.g., diazepam) decrease USVs (Garden & Hofer,
 
1990; Insel, Hill, & Mayor, 1986; Kehoe & Blass, 1986;
 
Kehoe & Boylan, 1992; Nazarian, Rodarte-Freeman, &
 
McDougall, 1999; Winslow & Insel, 1991b). However, drugs
 
that enhance USVs may do so by having either.
 
anxiogenic/aversive properties (Hansen, 1993; Mucha & Herz,
 
1985) or by directly activating neural pathways that
 
mediate USV production (Goodwin & Barr, 1997; Jiirgens,
 
1994). For example, the K-opioid agonist U50,488 and the
 
as-noradrenergic agonist cionidine increase the USVs of: ^
 
young rats (Barr, Wang, & Garden, 1994; Blumberg, SokOloff,
 
Kirby, & Kent, 2000; Hard, Engel, & Lindh, 1988; kehoe^^ &
 
Boylan-,,j1994; Kehoe & Harris, 1989; Nazarian et al. l-gsiS') i'.)
 
Cionidine- and U50,488-induced vocalizations are not
 
suppressed when the rat pup is placed back in the home cage
 
(Garden, Davachi, & Hofer, 1994; Hansen, 1993), suggesting
 
that these drugs may enhance USVs by stimulating pathways
 
mediating USV production (i.e., these actions may be
 
independent of the drug's aversive or anxiogenic
 
properties).
 
Various brain regions are involved in the production
 
of USVs. Receptor localization studies have shown the
 
presence of both K-opioid and noradrenergic receptors in the
 
striatum and amygdala, areas known to be important for
 
affective behaviors. Furthermore, USV production is
 
correlated with Fos-like immunoreactivity in the amygdala,
 
prefrontal cortex, and periaqueductal gray (PAG) of adult
 
rats (Fos is a quick-developing protein that can be used as
 
a regional marker of neuronal activation) (Duncan, Knapp, &
 
Breese, 1996). Additional evidence suggests that the PAG
 
may be of special importance, as microinjecting U50,488
 
into the PAG enhances USV production in young rats (Goodwin
 
& Barr, 1997). Finally, the amygdala and PAG are
 
extensively interconnected, suggesting that these two brain
 
regions may jointly mediate some behaviors, perhaps
 
including USVs (Rizvi, Ennis, Behbehani, & Shipley, 1991).
 
Taken together, these results suggest-that.USO,488 and
 
clonidine may affect USV production by stirriulating K-opioid
 
and noradrenergic receptors in the amygdala and/or PAG.
 
The cardiovascular model. In the past decade,
 
traditional views about USVs have been challenged by
 
studies questioning the validity of the distress model.
 
More specifically, Blumberg and colleagues argue that USVs
 
are by-products of a cardiovascular process known as the
 
abdominal compression reaction (ACR; Blumberg et al.,
 
1999). The ACR is a mechanism that helps move venous blood
 
back to the heart by the contraction of abdominal muscles
 
during expiration (Youmans, Tjide, & Tong, 1974). The
 
mechanisms involved in ACR-induced USVs are as follows. An
 
isolated rat pup has difficulty thermoregulating, thus its
 
body temperature decreases when isolated. This decrease
 
causes heart muscles to cool down and/ consequently, both
 
heart rate and blood pressure are reduced (Blumberg,
 
Sokoloff, & Kirby, 1997). The decrease in heart rate
 
causes a reduction of venous flow. Therefore, the ACR
 
assists in propelling the venous blood back to the heart
 
(Blumberg et al., 1999), Ultrasonic, vocalizations are,
 
therefore, a by-product of air released by the larynx
 
during expiration.
 
The young rat has a physiological mechanism that can
 
combat the decrease in body temperature. Rats as well as
 
Other mammals have brown adipose tissue (BAT) surrounding
 
critical organs in the body. The role of BAT is to assist
 
in thermoregulation when body temperature decreases (Smith,
 
1964). Thermoregulation occurs by increasing the
 
metabolism of BAT, resulting in an increase in temperature,
 
which then warms up the critical organs that it surrounds
 
(e.g., the heart; Smith, 1964). The heating of BAT
 
prevents heart muscles from cooling down,, thus preventing a
 
decrease in heart rate (Blumberg et al., 1997). The
 
ability of BAT to assist in thermoregulation is limited,
 
because extreme cold temperatures can overwhelm the
 
capacity of BAT to maintain the necessary temperature to
 
prevent the heart from slowing down (Blumberg et al., 1997;
 
Blumberg & Stolba, 1996). During such situations, the";'
 
animai involuntarily engages in ACRs to maintain blood
 
pressure and prevent further decreases of heart rate
 
(Youmahs et al;.,,l.1974:).-/.Due to .the inability, of BAT to­
.thermoregulate, USVs are emitted as by-products of the ACR.
 
As noted earlier, psychopharmacological manipulations
 
can alter USV levels, therefore it is possible that these
 
cardiovascular mechanisms can be activated using various
 
drugs. Interestingly, drugs that enhance USVs often affect
 
the cardiovascular system. For instance, both the K-opioid
 
agonist U50,488 and the as-noradrenergic agonist clonidine
 
decrease body temperature, heart rate, and blood pressure
 
of rats (Gautret & Schmitt, 1985; Ledda, Mantelli, & Corti,
 
1985; Szabo, Bock, Nordheim, & Niederhoffer, 1999).
 
Interestingly, K-opioid and as-noradrenergic systems
 
interact when modulating rabbit and guinea pig heart
 
functioning. For example, stimulation of K-opioid
 
receptors, located on peripheral noradrenergic nerve
 
terminals, inhibits the release of norepinephrine at the /
 
heart (Fuder, Buder, Riers, & Rothacher, 1986; Ledda et
 
al., 1985; Starke, Schoffel, & Illes, 1985). Similarly,
 
:stimulation of presynaptic'as-adrenoceptors in the,periphery.
 
also inhibits the release of norepinephrine at the heart
 
: (Korner et al., 1983; Van Zwieten, 1986). Inhibiting
 
norepinephrine release by K-opioid or a2-adrenoGeptor ^ '
 
stimulation decreases heart rate (bradycardia) (Fuder et
 
al., 1986; Van Zwieten, 1986). Centrally mediated
 
cardiovascular responses can decrease heart rate and blood
 
pressure asiwell. For instance, activation of K-opioid
 
feceptprs hippocampal and hypothalamic regions prbduces,
 
bradycardia and hypotension (Wang & Ingenito, 1994). Based
 
on the evidence presented, it is possible that U50,488 and
 
Clonidine increase USVs through either peripherally- or
 
centrally-mediated cardiovascular mechanisms.
 
■P: Summary and proposal. At present, USV production can 
be explained using either the distress model or the 
cardiovascular model. The distress model states that USVs 
are an emotionally-mediated behavior produced by rat pups 
when separated from their mother and littermates. These 
vocalizations are therefore emitted, either intentionally . 
or unintentionally, to attract the mother for nurturance, 
protection, and assistance in thermoregulation. The 
cardiovascular model, however, argues that USVs are simply 
by-products of ACRs. Thus, ultrasound production is 
10 
 considered to be a residual effect, as the young rat
 
invdlnhtarily engages in ACRs to drive venous blood back to
 
Athe: heart> , . .
 
■ Drug-induced changes in trsvs can be explained using 
both; the distress and cardiovascular models.. That is.,.. 
U50,488 and clonidine may increase USVs by: a) directly 
affecting neuronal mechanisms mediating distress, or b) 
altering heart rate, blood pressure and body temperature. 
Therefore, my long-term goal is to determine the underlying 
mechanisms by which K-opioid agonists and noradrenergic
 
agonists produce vocalizations. As an initial step, I want
 
to determine whether the K-opioid and as-noradrenergic
 
systems interact when mediating USV production.
 
K-Opioid and g-noradrenergic systems
 
K-Opioid and a-noradrenergic receptors are intimately
 
involved in USV production in young rats. For instance,
 
both the K-opioid agonist U50,488 and the a2-noradrenergic
 
agonist clonidine enhance USVs of neonatal and preweanling
 
rats (Garden et al., 1994; H^rd et al., 1988; Kehoe Sc
 
Boylan, 1994; Kehoe & Harris, 1989; Nazarian et al., 1999).
 
It is currently not known whether stimulation of the k-

opioid system is necessary for a-noradrenergic-induced
 
USVs. As noted earlier, it is possible that these two
 
systems interact either centrally or peripherally to
 
enhance USVs. Stimulation of a-noradrenergic or K-opioid
 
receptors located on noradrenergic nerve terminals in the
 
heart inhibits the release of norepinephrine, ' The reduced
 
levels of norepinephrihe cause bradyeardia, which may then
 
enhance- USVs; However, it is also possible that K-opioid
 
and noradrenergic systems interact in the - amygdala, -/
 
striatum, or PAG to increase USVs. To date, the
 
interaction of K-opioid and a-noradrenergic system on the
 
USVs of young rats has not been examined. Consequently,
 
studying how these two systems interact is crucial for
 
better understanding the underlying mechanisms responsible
 
for USV production.
 
K-Opioid receptors. Since the discovery of K-opioid
 
receptors in the early 1980's, three K-opioid receptor
 
subtypes have been characterized: Ki, K2, and K3 (Cheng,
 
Rogues, Gacel, Huang, & Pasternak, 1992; Fowler & Eraser,
 
1994; Leslie & Laughlin, 1994; Unterwald, Knapp, & Zukin,
 
1991). The K-i-opioid receptor subtype has a high affinity
 
for the endogenous peptide dynorphin A and exogenous
 
arylacetamide drugs such as U50,488 and U69,593 (Devlin &
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Shoemaker, 1990; Unterwald et al., 1991). The K2-opioid 
receptor has a higher affinity for dynorphin A and 
exogenous drugs such as bremazocine (Underwald et al., 
1991). Because of the limited understanding of Ks-opioid 
receptors, the only.drug that has specific affinity for 
this .recaptor subtype is naloxone benzoylhydrazone (Cheng 
et al., ■ 1992)., 
Ki-Opioid.receptors are found in various brain regions, 
including the striatum,■nucleus accumbens, olfactory 
tubercle, amygdala, central medial nucleus of the thalaraus, 
vehtral tagmental area, periagueductal gray, and substantia 
nigra pars reticulata (Mansour, Burke, Pavlic, Akil, & 
Watson, 1996; Unterwald et al., 1991) . In general, K2­
opioid receptors are found in greater densities in the 
brain than Ki-opioid receptors. K2-0pioid receptors have 
been localized in the striatum, nucleus accumbens, 
olfactory tubercle, claustrum, endopiriform nucleus, 
various thalamic regions, and inferior colliculus. 
(unterwald et al., 1991) . The limited number of studies 
examining Ks-opioid receptors suggest that they can be found 
in the thalamus, hypothalamic areas, hippocampus, striatum, 
and midbrain (Chengvet al., 1992) . Localization of K3­
13 
opioid receptors are based on homogenate receptor binding
 
assays (Cheng et al., 1992), while Ki-opioid and K2-opioid
 
receptor localization is based on receptor autoradiography
 
assays (Devlin & Shoemaker, 1990; Unterwald et al., 1991).
 
Receptor autoradiography is more appropriate for studying
 
regional differences in receptor topography than homogenate
 
receptor binding assays (Feldman, Meyer, & Quenzer, 1997,
 
pp. 31).
 
Behavioral effects of K-opioid receptor stimulation in
 
the adult rat. Stimulatibn of,. K-opioid receptors produces
 
antinociception in a variety of analgesia paradigms. For
 
instance, the K-opioid receptor agonist U50,488 increases
 
radiant heat tail-flick latencies and hind paw withdrawal
 
latencies in the formalin test, and decreases abdominal
 
licking to visceral pain (Craft, Henley, Haaseth, Hruby, &
 
Porreca, 1995; Idanpaan-Heikkila, Kalso, & Seppala, 1994;
 
McLaughlin, Tao, & Abood, 1995; Millan, Czlonkowski,
 
Lipkowski, & Herz, 1989). Moreover, the K-opioid antagonist
 
nor-BNI attenuates U50,488-induced antinociception (Craft
 
et al., 1995; McLaughlin et al., 1995; Millan et al.,
 
1989). Therefore, these results demonstrate that U50,488­
14
 
induced antinociception is mediated by activation of k-

opioid receptors.
 
K-Opioid receptor agonists produce a dose-dependent
 
decrease in the locomotor activity of adult rats and mice
 
(Jackson & Cooper, 1988; Leyton & Stewart, 1992; McLaughlin
 
et al., 1995; Ukai & Kameyama, 1985; VonVoigtlander, Lahti,
 
Sc Ludens, 1983). Thus, high doses (10 mg/kg) of U50,488
 
attenuate the locomotor activity of adult rats, while lower
 
doses (1 mg/kg) of U50,488 have no effect (Jackson &
 
Cooper, 1988; Ukai &:Kameyama, 1985). U50,488's
 
hypolocomotive effects are reversed by the K-opioid receptor
 
antagonist nor-BNI (Jones & Holtzman, 1992). In summary,
 
it is evident that K-opioid agonists reduce the locomotor
 
activity of adult rodents via stimulation of K-opioid
 
receptors.
 
In addition to producing analgesia and affecting
 
locomotor activity/ activation of K-opioid receptors appears
 
to have some aversive properties. For example, stimulation
 
of K-opioid receptors using U50,488 or dynorphin derivatives
 
(e.g., E-2078) results in conditioned place and taste
 
aversions (Bals-Kubik, Herz, & Shippenberg, 1989; Mucha &
 
Herz, 1985; Shippenberg & Herz, 1986; but see Crawford,
 
15
 
 McDougall, Bolanos, Hall, & Berger, 1995). Moreover, k-

opioid receptor stimulation has been shown to be aversive
 
when assessed in a self-administration paradigm (Pi Chiara
 
& Imperato, 1988b; Holtzman & Steinfels, 1994). Although
 
speculative, U50,488-induced aversions and hypolocomotion
 
may be due to K-opioid-mediated reductions in extracellular
 
dopamine in the nucleus accumbens and striatum (brain
 
regions known to mediate both reward and locomotor 
activity) (Di Chiara & Imperato, 1988a; Maisonneuve, Archer 
& Glick, 1994; Spanagel, Almeida, Bartl, & Shippenberg, 
1994). ;■ . 
Behavioral effects of K-opioid receptor stimulation in 
the preweanlinq rat Depending on the behavior, 
stimulation of K-opioid receptors may produce adult-typical 
or adult-atypical effects in preweanling rats. Unlike 
adults, stimulation of K-opioid receptors increases the 
locomotor activity of preweanling;rats. For example, both 
systemic and intranigral injections of K-opioid receptor 
agonists enhance the locomotor activity of 3 -, 10-, and 17­
day-old rats (Collins, Zavala, Nazarian, & McDougall, 2000; 
Duke, Meier, Bolanos, Crawford, & McDougall, 1997; Jackson 
Sc Kitchen, 1989; Kehoe & Boylan, 1994; McDougall, Rodarte­
■ ■ ■ ■ ■ 'O'- -i'' 16. 
Freeman, & Nazarian, 1999; McLaughlin et al., 1995). This
 
increase in locomotion is blocked by systemic, as well as
 
intranigral, injections of nor-BNI (Collins et al., 2000;
 
McLaughlin et al., 1995), thus indicating that K-opioid
 
agonists produce their locomotor activating effects by
 
stimulating K-opioid receptors in the substantia nigra pars
 
reticulata (Collins et al., 2000).
 
Similar to adults, preweanling rats given K-opioid
 
receptor agonists exhibit analgesic responses on tail-

flick, hot-plate, formalin, and mechanical pain tests
 
(Barr, Miya, & Paredes, 1992; Barr, Paredes, Erickson, &
 
Zukin, 1986; Giordano & Barr, 1988; Kehoe & Boylan, 1994;
 
McLaughlin et al., 1995; Nazarian et al., 1999). K-Opioid­
induced analgesia in the formalin test is blocked by the
 
selective K-opioid receptor antagonist nor-BNI (McLaughlin
 
et al., 1995). Analgesia produced by stimulation of k-

opioid receptors is mediated through both spinal and
 
superspinal sites (Barr et al., 1992; Goodwin, Wiedenmayer,
 
Sc Barr, 1998).
 
Of course, U50,488 greatly enhances USVs in neonatal
 
and preweanling rats (Barr et al.,. 1994; Garden, et al.,
 
1994; Kehoe & Boylan, 1994; Nazarian et al., 1999).
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U50,488-induced USVs may result from aversive properties of
 
the drug, or K-opioid receptors may directly mediate
 
distress-induced vocalizations. These results indicate
 
that preweanling rats have adult-typical analgesic and
 
aversive reactions to K-opioid agonists, while the
 
mechanisms responsible for K-opioid-mediated USVs and
 
distress are not well understood.
 
g-Noradrenergic receptors (adrenoceptors). Knowing
 
the neuroanatomical location and affinity of receptors is
 
important when studying the functional role of receptor
 
subtypes in the brain. Recent studies have categorized a­
adrenoceptors into two subtypes: ai and aa. ai-

Adrenoceptors are found primarily in the cerebral cortex,
 
striatum, thalamus, hypothalamus, hippocampus, pons,
 
medulla, cerebellum, and spinal cord (Wilson & Minneman,
 
1989). Moreover, tti-adrenoceptors are characterized by
 
having high affinities for agonist drugs such as
 
cirazoline, methoxamine, and phenylephrine. These
 
receptors also have high affinities for antagonists such as
 
prazosin, WB-4101, and phenoxybenzamine (Ruffolo, Nichols,
 
Stadel, & Hieble, 1991). ,
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aa-Adrenoceptors are found in somewhat different
 
regions than ai-adrenoceptors. For example, a2­
adrenoceptors are found in the locus coeruleus,
 
hypothalamus, basolateral and central amygdala, thalamus,
 
substantia nigra pars reticulata, dentate gyrus, striatum,
 
CAl pyramidal cells, and hippocampus (Wamsley, Alburges,
 
Hunt, & Bylund, 1992). Noradrenergic agonists such as
 
clonidine, a-methyl-norepinephrine, and UK-14,304 stimulate
 
a2-adrenoceptors, while yohimbine, idazoxan, and rauwolscine
 
antagonize a2-adrenoceptofs (Ruffolo et al., 1991).
 
Behavioral effects of a-adrenoceptor stimulation in
 
1
 
the adult and preweanling rat. Stimulation of a­
adrenoceptors by clonidine (an 0.2 preferring agonist)
 
results in the suppression of various behaviors in adult
 
rats. For instance, clonidine decreases the locomotor
 
activity, wall climbing, and nociception of adult rats
 
(Delini-Stula, Baumann, & Buch, 1979; Drew, Gower, &
 
Marriott, 1977; Fielding, Spaulding, & Lai, 1981; Fielding
 
et al., 1978; Reinstein & Isaacson, 1977; Smythe & Pappas,
 
1989). Moreover, stimulation of a2-adrenoceptors by
 
clonidine causes sedation, catalepsy, and suppresses
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avoidance acquisition (Kostowskiet al. > 1981; Laverty &
 
Taylor, 1969; Reinstein & Isaacson, 1977). The depressive
 
effects of clonidine are due to the stimulation of central
 
a2-noradrenergic autoreceptors which attenuate the release
 
of norepinephrine from nerve terminals (Delini-Stula et
 
al., 1979; Drew, Grower, & Marriott, 1977). Clonidine does
 
have some rewarding properties, because it produces
 
conditioned place preferences in adult rats (Asin &
 
Wirtshafter, 1985).
 
In contrast to adults, young rats show different
 
behavioral reactions to adrenoceptor agonists. More
 
specifically, stimulation of a2-adrenoceptors enhances USVs,
 
general motoric movement, wall climbing, antinociception,
 
and decreases olfactory place preference of home cage odor
 
(Blumberg et al., 1999; Hansen, 1993; Hard et al., 1988;
 
Kehoe & Harris, 1989; Smythe & Pappas, 1989). Clonidine­
induced USVs and locomotor activity are inhibited by
 
yohimbine and idazoxan (a2-receptof antagonists) in a dose-

dependent manner (Hard et al., 1988; Kehoe & Harris, 1989;
 
Nomura & Segawa, 1979). When considered together, it is
 
evident that stimulation of a-adrenoceptors produces
 
different behavioral effects in young pups than adult rats.
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thus indicating that the noradrenergic system undergoes
 
ontogenetic changes across the preweanling period.
 
Cardiovascular system
 
Effects of K-Opioid receptor stimulation on the
 
cardiovascular system. Numerous studies have shown the
 
presence of K-opioid receptors in rat heart (Tai, Jin,. Chan,
 
& Wong, 1991; Zhang, Wang, Xia, & Wong, 1997; Zimlichman et
 
al., 1996). Peripheral administration of endogenous and
 
exogenous K-opioid ligands (e.g., dynorphin (1-13) or
 
1750,488) decreases heart rate (bradycardia) and blood
 
pressure of adult rats (Gautret & Schmitt, 1985; Ledda et
 
al., 1985; Pugsley, Penz, Walker, Wong, 1992a,- 1992b;
 
Pugsley, Saint, Penz, & Walker, 1993). Interestingly, k-

opioid receptor agonists produce bradycardia through two
 
distinctly different mechanisms of action. At lower doses,
 
1750,488 produces bradycardia by stimulating K-opioid
 
receptors in the heart; while at higher doses 1750,488
 
produces bradycardia by blocking Na"^ and K'*' currents in
 
heart muscles (Gautret & Schmitt, 1985; Pugsley et al.,
 
1992a; Pugsley et al., 1993; Pugsley, Saint, & Walker,
 
1994; Wong, Lee, & Tai, 1990). When administered at lower
 
doses, 7750,488-induced bradycardia is blocked by the k­
.21,
 
opioid receptor antagonist MR 2266, or the non-selective
 
opioid antagonist naloxone (Wong et al., 1990). At higher
 
doses, U50,488-induced bradycardia is not affected by MR
 
2266 or naloxone (Pugsley et al., 1992a). Therefore, it
 
appears that K-opioid-induced bradycardia is mediated by two
 
different mechanisms in rat heart.
 
In addition to these peripherally mediated effects,
 
heart rate and blood pressure can be affected by central
 
administration of drugs. There are various brain regions
 
that, when stimulated, can alter heart rate and blood
 
pressure. For example, U50,488 infused into the
 
hippocampus or hypothalamus produces bradycardia and
 
hypotension; similar to the effects of peripherally
 
administered K-opioid agonists (Feuerstein & Faden, 1982;
 
Wang & Ingenito, 1994).
 
Altogether, at least two possible mechanisms of action
 
can account for K-opioid mediated bradycardia and
 
hypotension. Peripherally, K-opioid receptor stimulation at
 
the heart can produce bradycardia and hypotension. While,
 
central activation of K-opioid receptors in the hippocampus
 
or hypothalamus can also decrease heart rate and blood
 
pressure.
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 ; ; Effect of g-noradrenerqic receptor stimulation on the
 
cardiovascular system; .. the a-n is
 
intimately involved in the normal fuhctioning of the heart.
 
Consequently, modulation of the a-noradrenergic system
 
using agonist and antagdnist'drugs can. signifiGantly alter
 
heart/rate, and blood pressure of the organism. For .. . ■ 
instance, /stimulation of. cardiacV;ai;-^adrehoceptors by ..
 
endogenous or exogenous ligands increases heart rate and
 
blood pressure (Van Zwieiteh, Timmermans, & Van Brummelen,
 
1984;/Van Zwieten, Van Meel, &' Tot 1982). . In rat
 
heart, ai-adren6ceptors appear to be exclusively located on
 
postsynaptic terminals (Wagner & Brodde, 1978).
 
Unlike ai-adrenoceptors, a2-adrenoceptors are located
 
on presynaptic terminals in rat heart (Langer, 1981;
 
Starke, 1977; Westfall, 1977). Stimulation of tta- /
 
adrenoceptors by norepinephrine or.clonidine inhibits
 
norepinephrine release from presynaptic terminals (Korner
 
et al., 1983; Van Zwieten, 1986). Therefore, stimulation
 
of a2-adrenoceptors reduces blood pressure and heart rate in
 
rats by reducing norepinephrine levels at the heart (Korner
 
et al., 1983; Szabo et al., 1999). In summary, stimulation
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 of postsynaptic ai-adrenoceptors increases heart rate and
 
blood pressure, while stimulation of presynaptic a2­
adrenoceptors decreases heart rate and blood pressure.
 
Overview
 
: mentibnfed/:-tJSV^; has been
 
explhiried by two distinctly different models the distress
 
model and the cardiovascular model. Tlie distress model
 
suggests that USVs are an emotiOhaliy-mediated reaction
 
exhibited by young pups. ^This model; is supported by: ^
 
findings showing that young rats emit USVs when separated /
 
from their dam and littermates. Pharmacological findings
 
indicate that various drugs alter USV production. For
 
instance, morphine, cocaine, and diazepam reduce
 
vocalizations, while U50,488 and clonidine enhance
 
vocalizations.'
 
In opposition to the distress model, the
 
cardiovascular model suggests that the cardiovascular
 
system may be ultimately responsible for both U50,488- and
 
clonidine-induced vocalizations. That is, alterations in
 
the cardiovascular system due to isolation or drugs may
 
result in the production of USVs. Pharmacological evidence
 
indicates that both U50,488 and clonidine produce
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bradycardia, hypotension, and hypothermia. These
 
cardiovascular effects are important factors that can
 
activate ACRs and, thus, produce USVs. Therefore, it is
 
possible that isolation-ihduced and pharmacologically- "
 
induced USVs are due to cardiovascular mechanisms instead
 
of emotionally-induced reactions such as distress.
 
Altogether, it appears that activating K-opioid and
 
noradrenergic systems enhances USV production of
 
preweanling rats. This increase may be due to either
 
emotional- or cardiovascular-mediated actions. Because k-

opioid and noradrenergic agonist drugs increase USVs, it
 
appears that both the K-opioid and noradrenergic
 
neurotransmitter systems mediate USV production. It is
 
uncertain, however, whether these two neurotransmitter
 
systems interact to mediate USVs.
 
Thesis ;
 
The purpose of.this .theslS: was to determine whether
 
the K-opioid and a2-noradrenergic systems interact to
 
mediate USV production of preweanling rats. The
 
interaction of these systems was assessed by using the k-

opioid agonist U50,488, the K-opioid antagonist nor-BNI, the
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a2-noradrehe]rgic agonist: clonidine, and the a2-noradrenergic
 
antagonist yohimbine. .
 
Both USVs and line-crosseg (a reliable measure of
 
■ Ipcdmotor activity), were assessed in each experiment. In 
the first experiment, various doses of clonidine were
 
administered in order to determine a dose of clonidine that
 
would reliably prqduceUSVs. and line-crosses in young rats.
 
In the second experiment, the interaction of K-opioid and
 
d2-nbradrenergic systems was assessed by administering nor-

BNI in Combination with U50,488 or. clonidine. In the third
 
experiment, the interaction of K-opioid and a2-noradrenergic
 
systems was further assessed by administering yohimbine in
 
combination with clonidine or U50,488.
 
It was originally hypothesized that the pattern of
 
drug effects would differ depending on the dependent
 
measure (i.e., USVs, locomotor activity, and rectal
 
temperatures). When assessing USV production, it was
 
predicted that: 1) clonidine and would produce a
 
progressive dose-dependent increase in USVs; 2) nor-BNI
 
would attenuate U50,488- and clonidine-induced USVs, and 3)
 
yohimbine would attenuate clonidine- and U50,488-induced
 
USVs. This pattern.of results would indicate that K-opioid
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and a2-noradrenergic systems synergistically interact when
 
mediating USV production. The bases for these predictions
 
were three-fold: first, stimulation of both K-opioid and a2­
noradrenergic receptors enhances USV emissions; second, k-

opioid and a2-noradrenergic systems are known to have
 
extensive interactions in the periphery; and, third, USVs
 
are suspected to 'be peripherally mediated. Because of the
 
extensive peripheral interactions between K-opioid and a2­
noradrenergic systems, it was predicted that these two
 
neurotransmitter systems would interact to mediate USV
 
production.
 
A different pattern of drug-induced effects was
 
hypothesized for locomotor activity. It was predicted
 
that: 1) clonidine would produce a progressive dose-

dependent increase in line-crosses; 2) nor-BNI would
 
attenuate U50,488-, but not clonidine-, induced line-

crosses; and 3) yohimbine would attenuate clonidine-, but
 
not U50,488-, induced line-crosses. The bases for these,
 
predictions were two-fold: first, it is doubtful whether k-

opioid and a2-noradrenergic systems have extensive
 
interconnections in brain regions known to mediate
 
locomotor activity; and, second, K-opioid and a2­
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noradrenergic receptor agonists are suspected of
 
stimulating locomotor activity via central mechanisms
 
(Anden et al., 1970; Collins et al., 2000; Zebrowska-

Lupina, Prezegalihski, Sloniec, & Kleinrok, 1977). Because
 
of the lack of known central interconnections, it is
 
doubtful whether the K-opioid and a2-noradrenegic systems
 
interact to mediate locomotor activity.
 
Hypotheses about drug-induced changes in rectal
 
temperatures were based on previous findings. It was
 
predicted that clonidine, but not U50,488, would reduce
 
rectal temperatures of 11-day-old rats (Blumberg, Kreber,
 
Sokoloff, Sc Kent, 2000; Nazarian et al., 1999). It was
 
also predicted that yohimbine would attenuate clonidine­
induced reductions in rectal temperatures.
 
Future Directions ,
 
This research project was the first step in
 
determining whether: 1) the K-opioid and a-noradrenergic
 
systems interact when mediating USV production, 2) the k-

opioid and a-noradrenergic receptors mediating USVs are
 
located centrally or peripherally, and 3) USVs are the
 
result of distress or ACRs. In this study I directly
 
answered the first question, that is, whether the K-opioid
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and a2-noradrenergic systems interact when mediating USV
 
production. In subsequent projects I hope to build on
 
these results and provide answers for all three questions
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GENERAL. METHODS
 
Subjects
 
Subjects were 115 rats of Sprague-Dawley descent
 
(Harlan, Indianapolis, IN). Litters were culled to 10 pups
 
on postnatal day (PND) 3. An approximately equal number of
 
male and female rat pups were used in each experiment. All
 
rats were tested on PND 11. Animals were housed with their
 
dam and littermates prior to behavioral assessment. Rats
 
were randomly assigned to groups with no more then one rat
 
from each litter being placed in a particular group. To
 
maintain litter size, previously tested animals were
 
anesthetized with pentobarbital and placed back in the home
 
cage (Garden, Bartot, & Hofer, 1993). The colony room was
 
maintained at 22-24°C on a 12-hour light/dark cycle (lights
 
on at 6 a.m.).
 
Apparatus
 
Ultrasonic vocalizations and locomotor activity were
 
assessed in a Plexiglas chamber (19 x 19 x 19.5 cm) housed
 
inside a heated incubator (34°C). Rectal temperatures were
 
taken using a RET-3 rectal probe connected to a BAT-12
 
thermometer (Physitemp, Clifton, NJ). USVs were transduced
 
using a Mini-3 ultrasonic detector (Ultrasound Advice,
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London, England). An experimenter blind to treatment
 
conditions counted vocalizations.
 
Drugs
 
(±)-trans-U-50,488 methanesulfonate, nor­
binaltorphimine dihydrochloride (nor-BNI), clonidine
 
hydrochloride, and yohimbine hydrochloride (Sigma, St.
 
Louis, MO) were mixed in saline vehicle.at a volume of 5
 
ml/kg. All injections were given intraperitoneally (ip).
 
Statistical/Analysis
 
Analyses of variance (ANOVAs) were used to analyze
 
USVs, line-crosses, and rectal., temperatures. For all
 
analyses, litter effects were controlled using within-

litter statistical procedures (i.e., a within analysis with
 
one value/condition/iitter; Zorilla, 1997). in order to
 
assess sex-ihduced behavioral effects, USVs, line-crosses,
 
and body temperature data were reanalyzed with sex being
 
included as a factor in the statistical analyses. None of
 
these analyses resulted in statistically reliable effects,
 
so analyses including sex as a factor were not presented in
 
the text,. Post hoc analysis of simple interactions and
 
main effects,were performed using Tukey HSD tests (p < ­
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0.05). In these circumstances, Tukey tests were used to
 
compare drug groups to saline controls.
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 EXPERIMENT ,1
 
The first experiment was conducted to determine a dose
 
of clonidine that reliably stimulates USVs in 11-day-old
 
rats. It was predicted that clonidine would produce a
 
dose-dependent increase in USVs.
 
Method
 
Eight litters (N =40) of ll-day-old rats were
 
injected with clonidine (0.05, 0.1, 0.25, or 0.5 mg/kg, ip)
 
or saline and returned to the home cage for 15 min. Rats
 
were then individually transported to the testing room and
 
placed in the testing chamber. USVs and locomotor activity
 
were assessed for 20 min. Rectal temperatures were taken
 
immediately following testing.
 
In Experiment 1, separate one-way (agonist drug)
 
ANOVAs were used to analyze USVs, line-crosses, and rectal
 
temperatures. When appropriate, Tukey tests were used to
 
assess differences between drug groups and saline controls.
 
Results
 
Ultrasonic Vocalizations. USVs data were analyzed
 
using a one-way within-subjects ANOVA (see Appendix-A).
 
USVs of rats given clonidine are shown in Figure 1.
 
Clonidine produced a dose-dependent increase in the USV
 
production of 11-day-old rats [agonist drug main effect,
 
I ■ 
33
 
F(4, ;,2;8) ,, = 14.76, ;£ < 0.001]vi;'Specifically,v.the twov . - ;
 
highest doses of clonidine (0.25 and 0.5 mg/kg) produced ;
 
more USVs than saline [Tukey tests, p < 0.05].
 
Line-crosses. Line-cross data were analyzed using a
 
one-way within-subjects ANOVA (see Appendix B). Line-

crosses of young rats given clonidine are shown in Figure
 
2. , When compared to the saline group, all doses of
 
.clonidine caused a significant reduction in line-crosses
 
[agonist drug main effect, F(4, 28) = 4.93, p < 0.01, and
 
Tukey tests, p < 0.05].
 
Rectal Temperatures. Rectal temperature data were
 
analyzed using a one-way within-subjects ANOVA (see
 
Appendix C). Rectal temperatures of rats given clonidine
 
are shown in Figure 3. Rats treated with higher doses of
 
clonidine (0.1, 0.25, or 0.5 mg/kg) had significantly lower
 
rectal temperatures than saline-treated rat pups [agonist
 
drug main effect, F(4, 28) = 12.24, p < .001,. and Tukey ,(;
 
tests,
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Figure 1. Mean ultrasonic vocalizations (+SEM) of 11-day­
old,rats (n = 8) administered saline of clonidine (0.05,
 
0.1, 0.25, or 0.5 mg/kg) 15 min prior to behavioral
 
testing. ^Significantly different from saline-treated rats.
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Figure 2. Mean line-crosses (dSEM) of 11-day-old rats (n
 
8) administered saline or clonidine (0.05, 0.1, 0.25, or
 
0.5 mg/kg) 15 min prior to behavioral testing.
 
^Sgnificantly different from saline-treated rats.
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Figure .3. . Mean rectal temperatures (±SEM) of ll-day-old
 
rats (n = 8) administered saline or clonidine (0.05, 0.1,
 
0.25, or 0.5 mg/kg) 15 min prior to behavioral testing.
 
Rectal temperatures were measured immediately following the
 
20 min behavioral testing session, ^Significantly different
 
from saline-treated rats.
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EXPERIMENT 2
 
In the second experiment I assessed the potential
 
interaction between the K-opioid and a2-noradrenergic
 
systems. To do so, the K-opioid antagonist nor-BNI was
 
injected prior to treatment with the K-opioid agonist
 
U50,488 or the a-noradrenergic agonist clonidine. It was
 
predicted that K-opioid receptor blockade would attenuate
 
both K-opioid~mediated and a-noradrenergic-mediated USV
 
production.
 
Method
 
Eight litters (N = 72) of ll-day-old rats were
 
injected with nor-BNI (0, 5, or 10 mg/kg, ip) and placed in
 
their home cage for 15 min. Rat pups were then injected
 
with saline, USD,488 (2.5 mg/kg, ip) or clonidine (0.25
 
mg/kg, ip). After an additional 15 min, USVs and locomotor
 
activity were measured in the testing chamber for 20 min
 
(divided into four 5-min time blocks). Time blocks were
 
used to assess whether drug-induced effects varied as a
 
function of time. Rectal temperatures were taken
 
immediately after testing. Rat pups were then placed in a
 
room separate from their dam and littermates.
 
38
 
In Experiment 2, a 3 x 3 x 4 (antagonist drug x agonist
 
drug X time) within-subjects repeated measures ANGVA was
 
used to analyze USVs. Line-crosses and rectal temperatures
 
were analyzed using 3x3 (antagonist drug x agonist drug)
 
within-subjects ANOVAs.
 
Results
 
Ultrasonic Vocalizations. USV data were analyzed
 
using a 3 x 3 x 4 within-subjects repeated measures ANOVA
 
(see Appendix D). USVs of rats given nor-BNI and U50,488
 
or clonidine are shown in Figure 4. Overall, rats given
 
U50,488 or clonidine emitted more USVs than saline-treated
 
rats across all time blocks (all three graphs) [agonist
 
drug X time interaction, F(6, 42) = 6.20, p < 0.001, and
 
Tukey tests, p < 0.05], nor-BNI alone had no effect on USV
 
production (upper graph); however, both doses of nor-BNI (5
 
and 10 mg/kg) attenuated the U50,488-induced USV production
 
of 11-day-old rats (middle graph) [antagonist drug x agonist
 
drug interaction, F(4, 28) = 20.87, p < 0.001, and Tukey
 
tests, p < 0.05]. nor-BNI did not decrease clonidine­
induced USV production (bottom graph).
 
Line-crosses. Line-cross data were analyzed using a 3
 
X 3 within-subjects ANOVA (see Appendix E). Line-crosses of
 
39
 
rats given nor-BNI and U50,488 or clonidine are shown in
 
Figure 5. U50,488-treated rats had more line-crosses than
 
their saline controls, while clonidine had no effect
 
[agonist drug main effect, F(2, 14) = 68.44, p < 0.001, and
 
Tukey tests, p < 0.05]. nor-BNI (5 or 10 mg/kg) attenuated
 
U50,488-induced line-crosses in a dose-dependent manner,
 
whereas nor-BNI did hot affect line-crosses of saline- or
 
clonidine-treated rats [antagonist drug x agonist drug
 
interaction, F(4, 28) =11.84, p <0.001, and Tukey tests,
 
p < 0.05]. Curiously, the number of line-crosses exhibited
 
by saline-treated rats (M = 3.50) were less than in
 
Experiment 1 (M = 43.62). This was most likely due to
 
handling stress caused by multiple injections.
 
Rectal Temperatures. Rectal temperature data were
 
analyzed using a 3 x 3 within-subjects ANOVA (see Appendix
 
F). Rectal temperatures of rats given nor-BNI and U50,488
 
or clonidine are shown in Figure 6. Rats given clonidine
 
had lower rectal temperatures than saline controls [agonist
 
drug main effect, F(2, 14) = 30.21, p < 0.001, and Tukey
 
tests, p < 0.05]. When given alone^ neither U50,488 nor
 
nor-BNI affected rectal temperatures. nor-BNI did not
 
alter clonidine-induced reductions in rectal temperatures.
 
40
 
  
600-1
 
Saline
 
-O0 mg/kg nor-BNI
 
^5mg/kg nor-BNI
 
-■-10 mg/kg nor-BNI 
400­
200­
cn 
c " U50,488
 
;o
 
; 800­
03
 
N
 
CO o 600H 
o 
O' 
C 400-1 I(/) ■■ 
■M' - 200H 
Clohidine 
800­
600­
400­
200­
0­
5-Min Time Blocks 
4. Mean ultrasonic voGalizatidns ,(±SEM): of. ll-
old rats (n = 8) administered nor-BNI (0, 5, or 10 mg/kg) 
30 min prior to behavioral testing and saline, U50,48B (2.5
mg/kg/ ior clohidine , :(0.25; mg 15hnin pripr to behaviohal 
^Significantly different from rats given U50,488 
and 0 hng/kg nor-BNI collapsed aGrgss alT titne blOGks (^o 
41 
 300­
I 10 mg/kg nor-BNI 
250­ 1??^5 mg/kg nor-BNI 
1^^10 mg/kg nor-BNI 
(0 
0 200­
w 
w 
2 
O 150­ ab 
d) 
c. 
loo 
se­
0­
Saline U50,488 Clonidine
 
Agonist Treatment
 
Figure 5. Mean line-crosses (±SEM) of ll-day-old rats (n =
 
8) administered nor-BNI (0, 5, or 10 mg/kg) 30 min prior to
 
behavioral testing and saline, 1750,488 (2.5 mg/kg) or
 
clonidine (0.25 mg/kg) 15 min prior to behavioral testing.
 
^Significantly different from similarly treated rats given
 
saline; '^Significantly different from rats given 1750,488 and
 
0 mg/kg nor-BNI.
 
42
 
 37.0
 
36.5 I 10 mg/kg nor-BNI 
o 
o 
CO 
36.0­
5 mg/kg nor-BNI 
10 mg/kg nor-BNI 
2 
ZD 
35.5­ T 
2 
0 
Q. 
35.0­
34.5 
Lt 
E 
0 
1­ 34.0 
15 33.5­
"C 
0 
Q1 33.0­
32.5­
32.0
 
Saline U50,488 Clonidine
 
Agonist Treatnnent
 
Figure 6. Mean rectal temperatures (±SEM) of 11-day-old
 
rats (n = 8) administered nor-BNI (0, 5, or 10 mg/kg) 30
 
min prior to behavioral testing and saline, U50,488 (2.5
 
mg/kg), or clonidine (0.25 mg/kg) 15 min prior to
 
behavioral testing. Rectal temperatures were measured
 
immediately following the 20 min behavioral testing
 
session. ^Significantly different from saline-treated rats
 
collapsed across agonist treatment.
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EXPERIMENT 3
 
It was expected that nor-BNI would attehuate U50,488­
and clonidine-induced USVs. Therefore, in the third
 
experiment, the interaction of K-opioid and a2-noradrenergic
 
systems were further investigated by injecting yohimbine in
 
combination with clonidine or U50,488. I predicted that
 
yohimbine would cause a dose-dependent decrease in the 
. nhmber of'NS0,.'48 8 - ■ and clonidine-induced US . 
Method
 
litters (N = 72) of 11-day-old rats were
 
injected with yohimbine (0.0, 0.5, or 1.0 mg/kg, ip) and
 
placed: in their home cage for;15 min .^ ^ ::Rat pups were then;,, ■ 
ifijected with saline, USO,488 (2,5 ipf;
 
;(0;25: mg/kg^ ipjl After an additionai 15 min, USVs and^v ^
 
locomotor activity were measured in the testing chamber for
 
20 min (divided into four 5-min time blocks). Rectal
 
temperatures were taken immediately after testing. Rat
 
pups were then placed in a room separate from theirsdam and
 
littermates.
 
To analyze USVs, a 3 X 3 x 4 (antagonist drug x agonist
 
drug X time) within-subjects repeated measures ANOVA was
 
used. Line-crosses and rectal temperatures were analyzed
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using 3 X 3 (antagonist drug x agonist drug) within-subjects
 
ANOVAs.
 
Results
 
Ultrasonic Vocalizations. USV data were analyzed
 
using a 3 x 3 x 4 within-subjects repeated measures ANOVA
 
(see Appendix G). USVs of rats given yohimbine and U50,488
 
or clonidine are shown in Figure 7. Rats treated with
 
U50,488 or clonidine produced more USVs than saline-treated
 
rats [agonist drug main effect, F(2, 12) = 49.71, p <
 
0.001, and Tukey tests, p < 0.05]. Yohimbine (0.5 or 1.0
 
mg/kg) decreased USV emissions of saline-treated rats on
 
time blocks 1 and 2 (upper graph) [antagonist drug x agonist
 
drug X time interaction, F(12, 72) = 2.94, p <0.01, and
 
Tukey tests, p < 0.05]. Yohimbine also attenuated U50,488­
induced USV production in a dose-dependent manner.
 
Specifically, 0.5 mg/kg yohimbine decreased U50,488-induced
 
USV production on time blocks 1, 3, and 4 [Tukey tests, p <
 
0.05]; whereas, 1.0 mg/kg yohimbine decreased U50v488­
induced USVs on all time blocks (middle graph) [Tukey
 
tests, p < 0.05]. Both doses of yohimbine (0.5 or 1.0
 
mg/kg) deicreased clonidine-induced USV production on all
 
time blocks (bottom graph) [Tukey tests, p < 0.05].
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Line-crosses,. Line-cross data', were analyzed using a 3.
 
X 3 within-subjects ANOVA (see Appendix H). Line-crosses of
 
rats given yohimbine and U50,488 or clonidine are shown in
 
Figure 8. Rats given U50,48:8, but hot clonidine, had more
 
line-crosses than.saline-treated rats [Tukey tests, p <
 
0.05]. interestingly, both doses of yohimbine (0.5 and 1.0
 
mg/kg) attenuated U,50,488-induced line-crosses [antagonist
 
drug X agonist drug interaction, F(4, 24) = 9.55, p < 0.001,
 
and Tukey tests, p < 0.05]. Yohimbine did not affect line-

crosses of saline- or clonidine-treated rats. The total
 
number of line-crosses produced by saline-treated rats was
 
consistent with Experiment 2.
 
Rectal Temperatures. Rectal temperature data were
 
analyzed using a 3 x 3 within-subjects ANOVA (see Appendix
 
I). Rectal temperatures of rats given yohimbine and
 
U50,488 or clonidine are shown in Figure; 9. Once again,
 
clonidine-treated rats had lower rectal temperatures than
 
saline- or U50,488-treated rats [agonist drug main effect,
 
F(2, 12) = 27.00, p < 0.001, and Tukey tests, p < 0.05].
 
Overall, yohimbine did not affect the rectal temperatures
 
of rat pups.
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Figure 7. Mean ultrasonic vocalizations (±SEM) of 11-day­
old rats (n = 7) administered yohimbine (0.0, 0.5, or 1.0 
mg/kg) 30 min prior to behavioral testing and saline, 
U50,488 (2.5 mg/kg) , or clonidine (0.25 mg/kg) 15 min prior 
to behavioral testing. ^Significantly different from rats 
given 0.0 mg/kg yohimbine (open circles) . 
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Figure 8. Mean line-crosses (iSEM) of li-day-old rats (n =
 
7) administered yohirabine (0.0, 0.5, or l.G mg/kg) 30 min
 
prior to behavioral testing and saline, U50,488 (2.5 mg/kg)
 
or clonidine (0.25 mg/kg) 15 min prior to behavioral
 
testing. ^Significantly different from similarly treated
 
rats given saline;^'significantly different from rats
 
administered U50,488 and 0.0 mg/kg yohimbine.
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Figure 9. Mean rectal temperatures (±SEM) of 11-day-old
 
rats (n = 7) administered yohimbine (0.0, 0.5, or 1.0
 
mg/kg) 30 min prior to behavioral testing and saline,
 
U50,488 (2.5 mg/kg), or clonidine (0.25 mg/kg) 15 min prior
 
to behavioral testing. Rectal temperatures were measured
 
immediately following the 20 min behavioral testing
 
session. ^Significantly different from saline-treated rats
 
collapsed across agonist treatment.
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DISCUSSION
 
The purpose of the present study was to assess whether
 
the K-opioid and the a2-noradrenergic systems interact when
 
mediating USV production and locomotor activity of
 
preweanling rats. Similar to previous studies, saline-

treated rats emitted a moderate number of isolation-induced
 
USVs that decreased as the testing session progressed
 
(Blumberg, Efimova, & Alberts, 1992; Kehoe & Harris, 1989).
 
As predicted, clonidine increased the USV production of 11­
day-old rats in a dose-dependent manner (see Blumberg,
 
Kreber et al., 2000; Hansen, 1993; Hard et al., 1988; Kehoe
 
& Harris, 1989). Also, rat pups treated with U50,488
 
emitted more USVs than saline-treated rats (see Barr et
 
al., 1994; Garden et al., 1994; Kehoe & BoyIan, 1994;
 
Nazarian et al.,, 1999).
 
The interaction of K-opioid and a2-noradrenergic
 
systems was examined in two ways. First, by assessing the
 
effects of the K-opioid antagonist nor-BMI on U50,488- and
 
clonidine-induced USV production. Second, by assessing the
 
effects of the a2-noradrenergic antagonist yohimbine on
 
U50,488- and clonidine-induced USV production. In contrast
 
to my initial prediction, nor-BNI decreased U50,488-, but
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not clonidine-, induced USVs. Yohimbine, on the other
 
hand, decreased both U50,488- and clonidine-induced USVs.
 
Therefore, it appears that the K-opioid and a2-noradrenergic
 
systems interact when mediating USV production, but in a
 
more complex manner than originally hypothesized.
 
The K-opioid agonist affected locomotor activity in a
 
consistent manner, because rat pups treated with U50,488
 
had more line-crosses than saline-treated rats (see
 
Experiments 2 and 3). In contrast, clonidine's effects on
 
locomotor activity varied according to experiment. More
 
specifically, clonidine reduced the line-crosses of
 
preweanling rats in Experiment 1; whereas, clonidine did
 
not significantly affect line-crosses in Experiments 2 and
 
3. The inability of clonidine to decrease line-crosses in
 
the latter two experiments was probably due to a "basement
 
effect", as the saline controls exhibited minimal line-

crosses (M = 4.32) in Experiments 2 and 3 (i.e., a
 
clonidine-induced reduction in line-crosses was impossible
 
to detect). Both nor-BNI and yohimbine depressed U50,488­
induced locomotor activity, while neither antagonist
 
affected the locomotor activity of saline- or clonidine­
treateti rats.
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Rectal temperatures were differentially affeGted. by
 
the various drugs. Clonidine consistently reduced rectal
 
temperatures qf rat pups in all thrqe experiments. Op the
 
Other hand, U50,4.88 did not affectlrectal temperatures.
 
Neither ahtagonist wad able to block the clohidine-induced
 
reduction in rectal temperatures.
 
production: Role Of the a2-noradrenergic system. ;
 
As just mentioned, clonidine enhanced the USV production of
 
11-day-old rats. Clonidine-induced USVs can be explained ;
 
through at least three different mechanisms. First,
 
clonidine may stimulate aa-adrenoceptors in brain regions ;
 
involved with USV production. More specifically, clonidine
 
may induce USV production by stimulating a2-adrenoceptors in
 
brain regions involved with affective behaviors, such as ,
 
the amygdala, striatum, nucleus accumbens, and
 
periaqueductal gray (PAG).
 
Second, clonidine may indirectly enhance USV
 
production by affecting central pathways mediating
 
cardiovascular functioning. It has been previously shown
 
that clonidine stimulates a2-adrenoceptors in the medulla or
 
other brain stem nuclei involved in cardiovascular
 
functioning (Van Zwieten, 1986; 1996). This clonidine­
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induced stimulation may enhance USV production by
 
decreasing heart rate and blood pressure.
 
Third, clonidine may increase USV production by
 
directly stimulating presynaptic a2-adrenoceptors on nerve
 
terminals synapsing the heart. Direct stimulation of
 
presynaptic a2-adrenoceptors inhibits the release of
 
norepinephrine and decreases heart rate and blood pressure
 
(Drew,- 1976; Misu, Fujie, & Kubo, 1982). Altogether, it
 
appears that clonidine may induce USVs by: 1) producing a
 
State of emotional distress in the rat pup that results in
 
USV emissions, 2) modulating circuitry in the brain stem
 
involved with heart functioning, or 3) directly acting on
 
peripheral noradrenergic neurons that decrease heart rate
 
and, thus, increase USVs.
 
USV production: Role of the K-opioid system. Similar
 
to previous studies, U50,488 increased the iJSV production
 
of 11-day-old rats (Barr et al., 1994; Garden et al., 1994;
 
Kehoe & Boylan, 1994; Naz;arian et al., 1999). One
 
possibility is that U50,488 stimulates USV production by
 
activating K-opioid receptors in the striatum, nucleus
 
accumbens, amygdala; or PAG (i.e., brain regions known to
 
be involved in affective behaviors). Alternatively,
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U50,488 may activate K-opioid receptors in brain regions
 
involved in cardiovascular functioning. For instance,
 
stimulation of K-opioid receptors in the hippocampus,
 
hypothalamus, and medulla decreases the heart rate and
 
blood pressure of adult rats (Feuerstein & Faden, 1982;
 
Hassen, Feuerstein, & Faden, 1984; Wang & Ingenito, 1994).
 
The decreased heart rate could, in turn, be responsible for
 
the increased USV emissions.
 
It is also possible that activating peripheral K-opioid
 
receptors may enhance USV emissions of rat pups.
 
Stimulation of K-opioid receptors, located on noradrenergic
 
nerve terminals at the heart, decreases heart rate and
 
blood pressure (Fuder et al., 1986; Ledda et al., 1985;
 
Starke et al., 1985). Hence, the decrease in heart rate
 
and blood pressure may increase USV production. Therefore,
 
similar to clonidine, U50,488 may enhance USVs by: 1)
 
producing a state of emotional distress by acting on brain
 
regions involved in affective behaviors, 2) modulating
 
brain circuitry concerned with heart functioning, or 3)
 
directly inhibiting the release of norepinephrine at the
 
heart. Taken together, it is possible that U50,488 and
 
clonidine may produce USVs through similar mechanisms.
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Role of the K-opioid system on aa-noradrenergic­
mediated USV production. As noted earlier, the purpose of
 
this study was to assess the interaction between the k-

opioid and the a2-noradrenergic systems. The present study
 
showed that nor-BNI attenuated U50,488-induced USV
 
production of 11-day-old rats in a dose-dependent manner.
 
On the other hand, nor-BNI (a K-opioid antagonist) did not
 
reduce the USVs of rats given clonidine (a a2-noradrenergic
 
agonist). Thus, results from this particular experiment
 
suggest that the K-opioid system does not modulate a2­
noradrenergic-mediated USV production.
 
Role of the a2-noradrenergic system on K-opioid
 
mediated USV production. Other evidence suggests that the
 
K-opioid and a2-noradrenergic systems interact when
 
mediating USV production. Specifically, it appears that
 
the a2-noradrenergic system modulates K-opioid-mediated USV
 
emissions, as yohimbine decreased both U50,488- and
 
clonidine-induced USV production in a dose-dependent
 
manner. Yohimbine also reduced the USVs of saline-treated
 
rats. ,
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Based on this pattern of results, it appears that the
 
a2-noradrenergiG system modulates K-opioid-medisted USV
 
prodUGtion. Gonversely, manipulation of the K-opioid system
 
had no effeot on a2-noradrenergiG-mediated USVs. Therefore,
 
the K-opioid and az-noradrenergio systems seem to interaot
 
in a unidireotional manner. The most parsimdnidus
 
explanation is that the K-opioid reoeptors modulating USV
 
produGtion are loeated "up-stream" from the oritioal a2­
noradiehergic neurons. For instance, the K-opioid system
 
may mediate USV pidduotion'through higher brain oenters
 
(e.g., the striatum or PAG), while the a2-noradrenergiG
 
system may mediate USV production through brain stem areas.
 
Due to this unidireotional arrangement, the a2-noradrenergic
 
system would be able to alter K-opioid-mediated USV
 
produGtion, but the reverse would not be true.
 
The interaotion between K-opioid and a2-noradrenergiG
 
systems on looomotor aotivity. In the present study,
 
Glonidine-treated 11-day-old rats had fewer line-Grosses
 
than saline oontrols. This result is somewhat ourious
 
beoause a number of studies have reported that olonidine
 
enhanoes looomotor aotivity of rat pups (Kehoe & Harris,
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1989; Nomura & Segawa, 1979; Pappas & Walsh, 1983;
 
Reinstein & Issacson, 1977; Smythe & Pappas, 1989). This
 
inconsistency is most likely due to the method of assessing
 
locomotor activity. Studies that operationally define
 
locomotor activity in terms of line-crosses (a direct
 
measure of forward locomotion) typically report that
 
clonidine reduces locomotion (Hansen, 1993; present study);
 
whereas, studies that operationally define locomotor
 
activity in terms of general motoric movement (i.e., by
 
collapsing such measures as forward locomotion, paddling,
 
circling, and wall climbing) find that clonidine enhances
 
movement (Kehoe & Harris, 1989; Nomura & Segawa, 1979;
 
Pappas & Walsh, 1983; Reinstein & Issacson, 1977; Smythe &
 
Pappas, 1989). Consequently, it is likely that clonidine
 
reduces the locomotor activity of preweanling rats, while
 
increasing general motoric movement.
 
Stimulation of K-opioid receptors produces a
 
paradoxical increase in the locomotor activity of rat pups.
 
That is, K-opioid agonists (e.g., U50,488 and enadoline)
 
decrease locomotor activity of adult rats, while increasing
 
the locomotor activity of preweanling rats (Garden et al.,
 
1994; Crawford et al., 1995; Kehoe & Boylan 1994; McDougall
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et ai./ 1999; McLaughlin et al.y 1995; VonVoigtlander et
 
al., 1983). Gonsistent with past studies, US0,488 produced
 
a nor-BNI reversible enhancement in the locomotor activity
 
of ll-day-old rats (see also Collins et al., 2000;
 
McLaughlin et al., 1995).
 
Ah unexpected finding was that yohimbine reduced
 
US0,488-induced locomotor activity. Although not
 
previously shown, it is possible that a2-noradrenergic and
 
K-bpioid systems interact to decrease USO,488-induced
 
locbmotor activity. This suggestion, however, requires
 
further investigation. An alternative possibility is that
 
yohimbine may decrease USO,488-induced locomotor activity
 
by altering dopamine system functioning. Evidence for this
 
possibility is three-fold. First, yohimbine antagonizes,
 
dopamine bs-like receptors (Heal et al., 1987; Scatton,
 
Zivkovic, Sc Dedek, 1980). Second, yohimbine attenuates
 
amphetamine- and apomorphine-induced locomotor activity of
 
adult rats (Heal et al., 1987,* Luttinger & Durivage, 1986).
 
Importantly, the doses of yohimbine (1 and 3 mg/kg) found
 
to attenuate amphetamine- and apomorphine-induced locomotor
 
activity were similar to those used in the present study.
 
Third, dopamine antagonists attenuate USO,488-induced line­
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crosses in rat pups (Duke et al., 1997; Mazarian. et al.,
 
1999). It should be noted that:yohirabine does not reduce
 
USy production by blocking D2-like receptors because
 
dopamine antagonists have no effect on USV production of
 
rat pups (Dastur, McGregor, & Brown, 1999; Nazarian et al.,
 
1999).
 
The,role of .K-opioid and a.2-noradrenergic systems on 
rectal temperatures Consistent with past studies, 
clonidine reduced rectal temperatures of ll-day-old rats 
(Hard et al., 1988). On the other hand, U50,488 did not 
reduce rectal temperatures. . This may be due to the low ■ . 
dose (2.5 mg/kg) of U50,488 used in this study, because 
higher doses of U50,488 reduce rectal and axillary 
temperatures of rat pups (Garden et al., 1993; Nazarian et 
al., 1999). Interestingly, neither nor-BNI nor yohimbine 
had any effect on the clonidine-induced reduction of rectal 
temperatures. When considered together, these findings 
suggest that U50,488- and clonidine-induced USV production 
is independent of drug-induced changes in body temperature. 
Conclusion. Overall, the results of the present study
 
demonstrate that the K-opioid and a2-noradrenergic systems
 
interact when mediating USV production. This study does
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not conclusively resolve whether USV production is a
 
central or peripheral effect, or whether USVs are the
 
result of distress or a cardiovascular mechanism.
 
By combining both current and previous findings, it is
 
possible to suggest a number of mechanisms that may be
 
responsible for USV production. Although speculative, USV
 
production may be a distress response mediated by brain
 
regions involved in both affective and cardiovascular
 
functioning. Specifically, in adult rats, distress can be
 
induced by various procedures (e.g., restraint, shock, and
 
tail-pinch), all of which increase norepinephrine leyels i^^
 
the amygdala, basal ganglia, hippocampus, hypothalamus,
 
pens, and medulla (Quirarte, Galvez, Roozendaal, & McGaugh,:
 
1998; M. Tanaka et al., 1983; T. Tanaka et al., 1991).
 
These brain regions are, involved,in both affectiye:^^.:^ , ­
(amygdala and basal ganglia) and cardiovascular
 
(hippocampus, hypothalamus, pons, and medulla) functioning.
 
It is possible that young rats may show similar increases
 
in distress-induced norepinephrine levels. If this is
 
true, then it may explain the underlying mechanisms
 
responsible for USV production. That is, distress may
 
increase norepinephrine levels in brain regions involved in
 
affective and cardiovascular functioning. The increase in
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 norepinephrine levels may deGrease blood pressure and heart
 
rate and provoke USV emissions.
 
It is clear that USVs can be produced by distressing
 
the rat pup or by independently altering the cardiovascular
 
system. However, one should consider that both mechanisms
 
may be jointly involved in producing USVs. That is, when
 
an organism is crying, yelling, sneezing, or laughing,
 
physiological mechanisms are involved that cause air to be
 
exhaled from the larynx. Nonetheless, affect is inherently
 
involved because voluntary actions (e.g., laughing or
 
crying), similar to involuntary actions (e.g., sneezing),
 
also activate the same physiological mechanisms (i.e., air
 
exhaled from the larynx). When considering the adult and
 
pup distress literature together, it appears that
 
isolation-induced USV production is an emotionally-mediated
 
behavior that requires the participation of brain regions
 
involved in both affective and cardiovascular functioning.
 
Synopsis. The present study was a first step in
 
trying to better understand the underlying mechanisms
 
responsible for USV production. The function of USVs has
 
been of great dispute in recent years (Blumberg, Sokoloff
 
et al., 2000; Hofer & Shair, 1993). , According to the
 
distress model, USVs are interpreted to be an emotionally­
, '■ ■ ■ ■ ■' ' :■ ''v. : 6l : ■■ i.' V'' ■ ■ 
mediated behavior produced by rat pups in order to gain the
 
attention of the dam for nurturance, protection, and
 
thermoregulation (Bell, 1979; Smotherman et al., 1974).
 
This model interprets USVs as a distress call emitted by
 
rat pups, which can be modulated by various pharmacological
 
agents known to alter distress and anxiety. For instance,
 
drugs that reduce USV production are considered to be
 
rewarding (e.g., cocaine and morphine) or anxiety reducing
 
(e.g., diazepam), while drugs that enhance USVs (e.g., ,
 
U50,488) are considered to be aversive or anxiogenic
 
(Garden et al., 1990; 1994; Insel et al., 1986; Kehoe &
 
BoyIan, 1992). Therefore, according to the distress model,
 
USVs are emotionally-mediated voluntary behaviors that are
 
produced by rat pups when distressed.
 
In direct opposition, the cardiovascular model
 
suggests that USVs are simply by-products of abdominal
 
compression reactions (ACR). It is believed that rat pups
 
produce USVs in order to maintain their normal heart rate,
 
blood pressure, and body temperature when separated from
 
the dam (Blumberg et al., 1999). The cardiovascular model
 
postulates that drugs that enhance or reduce USV production
 
either directly or indirectly modulate cardiovascular
 
functioning through either central or peripheral mechanisms
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(Blumberg, Kreber et al., 2000). Thus, drugs that cause a
 
decrease in heart rate and blood pressure enhance USV
 
production. On the other hand, drugs that increase heart
 
rate and blood pressure reduce USV production. Taken
 
together, proponents of the cardiovascular model discount
 
the distress model and argue that USVs are a physiological
 
response with no affective cause.
 
In the present study, the K-opioid agonist U50,488, and
 
the a2-noradrenergic agonist clonidine independently .
 
enhanced USV production. I attempted to attenuate U50,488­
and clonidine-induced USV production by using the K-opioid
 
antagonist nor-BNI and the a2-noradrenergic antagonist
 
yohimbine. By doing so, I was interested in learning
 
whether the K-opioid and the a2-noradrenergic systems
 
interact when mediating USV production. Results showed
 
that the K-opioid and the a2-noradrenergic systems interact
 
in a very specific manner. The findings demonstrate that
 
U50,488-induced USV production was attenuated by nor-BNI
 
and yohimbine, while clonidine-induced USV production was
 
reduced by yohimbine but not nor-BNI. This pattern of
 
results suggests that the a2-noradrenergic system modulates
 
K-opioid-mediated USV production, but that the K-opioid
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system does not modulate aa-noradrenergic-mediated USV
 
production.
 
It is possible that USVs are emotionally-mediated
 
calls that require the joint activation of both affective
 
and cardiovascular centers in the brain. This conclusion
 
is supported by findings showing that both distress and
 
anxiety increase norepinephrine levels in brain regions
 
involved in affective and cardiovascular functioning. In
 
turn, USV emissions may ultimately be produced by changes
 
in cardiovascular functioning and the onset of ACRs.
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 Appendix A 
ANOVA 'Table for USV Data of Experiment 1 
Source SS : df ": ^ : MS. ■■ 
Total 16352588.98 39 2831246.44.
 
3388146.98/ r 7 484021.00
 
Agonist (Agon) ; 8792978.35 / 4 2198244,60 14.76 <0,001
 
> ErrorAgon( 4171463.65 . ' 28 148980.84
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Appendix B
 
ANOVA Table for Line-Cross Data of Experiment 1
 
Source SS df MS
 
Total 27553.10 39 3483.16 
Siubject 3209.90 7 458.56 
Agonist (Agon) 10057.60 4 2514.40 4.93 < 0.01 
ErrorAgon 14285.60 28 510.20 
<j\
 
CTi
 
Appendix C >
 
ANOVA Table for Rectal Temperature Data of Experiment 1
 
Source SS df MS F
 
Total 31.36 39 5.20
 
Subject 6.71 7 0.96
 
Agonist (Agon) 15.68 4 3.92 12.24 < 0.01
 
ErrorAgon 8.97 28 0.32
 
CTi
 
<1
 
Appendix D
 
ANOVA Table for USV Data of Experiment 2
 
Source SS df MS
 
Total 17462694.01 287 5811937.04 
Subject 266870.72 7 38124.39 
Antagonist (Antag) 2884143.56 2 1442071.80 43.91 < 0.001 
Agonist (Agon) 5928019.77 2 2965009.90 55.91 < 0.001 
Time 8275.03 3 2758.34 1.39 < 0.275 
Antag x Agon 4677555.42 4 1169388.90 20.87 < 0.001 
Antag x Time 62832.24 6 10472.04 2.14 < 0.068 
Agon X Time 143260.45 6 23876.74 6.20 < 0.001 
Antag x Agon x Time 54524.28 12 4543.69 1.48 < 0.146 
cr\ 
CX) Errorantag, 459798.55 14 32842.75 
ErrorAgon . 742234.84 14 53016.77 
ErrorTime 41781.81 21 1989.61 
ErrOrAntagxAgon 1569172.64 28 56040.81 
ErrorAntagxTime 205296.09 42 4888.00 
ErrOrAgonxTime 161788.05 42 3852.10 
ErrOrAhtagxAgonxTime 257140.56 84 3061.20 
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ANOVA Table for Line-Gross Data of Experiment 2
 
Source
 
Total
 
Subject
 
Antagonist (Antag)
 
Agonist (Agon)
 
Antag x Agon
 
ErrorAiitag^ ,
 
ErrorAgoH^. ; , .r
 
■ \ . ErrOrAntagxAgon 
Ch
 
vo
 
SS df : MS 
124137.62 71 38423.85 
v !1905:78 , 7 272.25 
1672':7;:86; 72^ 8363.93 11.90 < 0.001 
40016.72 2 20008.36 68.44 : < 0.001 
:32400.66 8100.16 11.84 <0.001: 
: 983E.81 .14 : 702^.63 
4092:95 392.35 
19156.84 684.17 
 Appendix F
 
AMOVA Table for Rectal Temperature Data of Experiment 2
 
Source SS df MS
 
Total
 
Antagonist (Antag)
 
Agonist (Agon)
 
Antag x Agon
 
, ; , : Errorjtotag /
 
'ErrorAgon ^
 
ErrOrAntagxAgon
 
94.84' 71 26.42 
26.16 :7 3.74 
0il5 2 0,08 0.19 0.829 
41.59 yi 20.79 30.21 0:001 
1.40 4 0.35 0.95 0.450 
5.57 .14 0.40 
9.64 14 0.69 
10.33 28 0.37 
<1
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 Appendix G
 
ANOVA Table for USV Data of Experiment 3
 
Total
 
<!
 
Source
 
ect
 
Antagonist (Antag)
 
Agonist (Agon)
 
Time
 
Antag x Agon
 
Antag x Time
 
Agon X Time
 
Antag x Agon x Time
 
ErrorAntag
 
ErrorAgon
 
ErrorTime
 
ErrOrAntagxAgon
 
ErrorAntagxTime
 
ErrorAgonxTime
 
ErrorAntagxAgonxTime
 
SS 

10233072.89
 
252476.22
 
1921607.72
 
4505085.77
 
10350.23
 
640540.49
 
16963.71
 
49387.28
 
79476.46
 
287476.11
 
543728.56
 
73045.46
 
1509995.17
 
87304.68
 
93251.28
 
162383.65
 
df 

251
 
6
 
2
 
2
 
3
 
4
 
6
 
6
 
12
 
12
 
12
 
18
 
24
 
36
 
36
 
72
 
MS
 
3580205.23
 
42079.37
 
960803.86
 
2252542.90
 
3450.08
 
160135.1,2
 
2827.28
 
8231.21
 
6623.04
 
23956.34
 
45310.71
 
4058.08
 
62916.47
 
2425.13
 
2590.31
 
2255.33
 
40.11
 
49.71
 
0.85
 
, . 2.55
 
1.17
 
3.18
 
2.94
 
< 0.001
 
< 0.001
 
< 0.485
 
< 0.066
 
< 0.346
 
< 0.013
 
< 0.002
 
Appendix H 
ANOVA Table for Line-Cross Data of Experiment 3 
Source SS df MS 
Total 
Subject 
Antagonist (Antag) 
Agonist (Agon) 
Antag x Agon 
ErrorAntag 
ErrorAgon 
Er r OrAntagxAgon 
331940.42 
21131.97 
22781.56 
178406.89 
35692.25 
14854.89 
36642.89 
22429.97 
62 
6 
2 
2 
4 
12 
12 
24 
118265.33 
3521.99 
11390.78 
89203.44 
8923.06 
1237.91 
3053.57 
934.58 
9.20 
29.21 
9.55 
< 0.004 
< 0.001 
< 0.001 
<1 
to 
Appendix I 
ANOVA Table for Rectal Temperature Data of Experiment 3 
Source SS df MS F P 
Total 
Subject 
Antagonist (Antag) 
Agonist (Agon) 
Antag x Agon 
ErrorAntag 
ErrorAgon 
ErrOrAntagxAgon 
67.38 
19.26 
0.28 
15.71 
2.85 
9.40 
3.49 
16.39 
62 
6 
2 
2 
4 
12 
12 
24 
13.66 
3.21 
0,14 
7.85 
0.71 
0.78 
0.29 
0.68 
0.18 
27.00 
1.04 
< 0.841 
< 0.001 
< 0.406 
<1 
U) 
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